Skip to main content
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRVI ISIN · US89532M1018 US Manufacturing
Open in API
Filings indexed 505 across all filing types
Latest filing 2023-08-14 Director's Dealing
Country US United States of America
Listing US TRVI

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com/

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary program is aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent a significant unmet medical need with no approved therapies in the United States. Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting both central and peripheral nerve pathways believed to cause chronic cough. The company has reported positive results from its Phase 2b CORAL trial in IPF chronic cough and its Phase 2a RIVER trial in refractory chronic cough.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-08-14 English
S-3/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC, dated August 11, 2023. It is a registration statement under the Securities Act of 1933 for the offering of securities including debt securities, common stock, preferred stock, units, and warrants. The document includes a base prospectus and a sales agreement prospectus describing the terms of securities offerings up to $200 million. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to securities registration and offering. The document is lengthy (15,000 characters) and contains detailed legal and offering information typical of a registration statement amendment. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories like Annual Report, Earnings Release, or Capital/Financing Update.
2023-08-11 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2023, reporting the company's financial results for the quarter ended June 30, 2023. It includes a press release as an exhibit announcing these results. The text explicitly states that the information is furnished and not filed, and it is a current report rather than a full quarterly or annual report. The document is relatively short (3677 characters) and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or analysis. Therefore, it fits the definition of an Earnings Release (ER) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2023-07-12 English
Regulatory Filings 2023
Regulatory Filings Classification · 90% confidence The provided document text appears to be heavily encoded or corrupted, containing no readable or meaningful financial, corporate, or regulatory information. There are no discernible keywords, regulatory references, form names, fiscal periods, or report titles that would allow classification into any specific filing category. The text does not contain any clear financial data, management discussion, voting results, or announcements. Given the lack of identifiable content and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS).
2023-07-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.